A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease

Summary

This Phase 2a, multicenter, open-label, dose-escalation study is designed to assess the safety and biologic activity of daily oral administration of 4 escalating doses of sapropterin dihydrochloride over 16 weeks in subjects with sickle cell disease. During an optional extension phase, the study will assess the safety, tolerability, and efficacy of extended treatment with sapropterin dihydrochloride, for a total of up to 2 years; The extension phase of this study was terminated.

Timeline

Start

2007-05

Primary completion

2008-08

Completion

2009-06

Drugs

Indications